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Abstract
Placental cortisol is inactivated in normotensive pregnancies, but is frequently present in pre-eclampsia associated
placentae. Since glucocorticoids are strongly associated with the programming of long-term health, we assessed DNA
methylation of genes involved in cortisol signalling and bioavailability, and hormonal signalling in the placenta of
normotensive and hypertensive pregnancies. Candidate genes/CpG sites were selected through analysis of Illumina Infinium
HumanMethylation450 BeadChip array data on control (n = 19) and early onset pre-eclampsia (EOPET; n = 19) placental
samples. DNA methylation was further quantified by bisulfite pyrosequencing in a larger cohort of control (n = 111) cases, in
addition to EOPET (n = 19), late onset pre-eclampsia (LOPET; n = 18) and normotensive intrauterine growth restriction
(nIUGR; n = 13) cases. DNA methylation (percentage points) was increased at CpG sites within genes encoding the
glucocorticoid receptor (NR3C1 exon 1D promoter; +8.46%; P,0.01) and corticotropin releasing hormone (CRH) binding
protein (CRHBP intron 3; +9.14%; P,0.05), and decreased within CRH (59 UTR; 24.30%; P= 0.11) in EOPET-associated
placentae, but not in LOPET nor nIUGR cases, compared to controls. Differential DNA methylation was not observed among
groups at the 11b-hydroxysteroid dehydrogenase type 2 (HSD11B2) gene promoter. Significant hypomethylation was
observed in pre-eclampsia but not nIUGR placentae for steroidogenic genes, including CYP11A1 (exon1; EOPET; 29.66%;
P,0.00001, and LOPET; 25.77%; P,0.001), 3b-hydroxy-delta-5-steroid dehydrogenase type 1 (HSD3B1 exon 2; EOPET;
212.49%; P,0.00001, and LOPET; 26.88%; P,0.001), TEA domain family member 3 (TEAD3 intron 1; EOPET; 212.56%;
P,0.00001) and CYP19 (placental-specific exon 1.1 promoter; EOPET; 210.62%, P,0.0001). These data represent
dysregulation of the placental epigenome in pre-eclampsia related to genes involved in maintaining the hormonal
environment during pregnancy and highlights particular susceptibility in the early onset syndrome.
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Introduction
Maternal stress and/or elevated glucocorticoid exposure in utero
is associated with low birth weight, exaggerated infant stress
response and adult disease in the offspring [1]. Disorders during
pregnancy which alter maternal physiology and induce systemic
inflammatory response are likely to augment stress-signalling
pathways, and may be associated with adverse developmental
programming. Pre-eclampsia, particularly that of early onset, is
largely the result of poor placentation, leading to hypoxic and
inflammatory insult to surrounding tissue as well as under-
perfusion of essential materials from mother to fetus [2–4]. Further
maternal complications can include necrosis of the liver, respira-
tory distress syndrome and seizures of eclampsia [5]. Clinically,
pre-eclampsia is a common obstetrical complication in developed
countries and remains a leading cause of maternal death [6],
however, its aetiology is poorly understood. In this study we aim to
determine how placental stress-pathways might be altered in pre-
eclampsia and related pregnancy complications.
Cortisol is responsible for the physiological ‘stress response’,
mediated through binding to the glucocorticoid receptor (GR)
gene (nuclear receptor subfamily 3, group C, member 1 [NR3C1])
[7]. The release of cortisol may be triggered by a number of
stimulatory cues to regulate immune response, cardiovascular
function, metabolism and reproductive function [8]. Corticotropin
releasing hormone (CRH) initiates this stress response through the
hypothalamic pituitary adrenal (HPA) axis. Large quantities of
placental CRH, identical to the hypothalamic form, are synthe-
sised and secreted by the syncytiotrophoblast [9,10] and stimulate
both the maternal and fetal pituitary to release adrenocorticotro-
pin hormone (ACTH), thus inducing adrenal cortisol secretion
[11–13]. In the placenta, CRH has multiple roles including the
stimulation of estrogen synthesis [14] and increasing the availabil-
ity of maternal glucose for placental uptake [15]. In contrast to
hypothalamic CRH control, cortisol positively stimulates CRH
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production in the placenta [16,17]. CRH activity is controlled by
sequestration to plasma CRH binding protein (CRHBP), thus
regulating the levels of bioactive free CRH [13].
In the placenta, cortisol is inactivated by 11b-hydroxysteroid
dehydrogenase type 2 (11b-HSD2), encoded for by HSD11B2
[18]. Dysregulation of HSD11B2 in the placenta is linked to the
detrimental actions of cortisol in offspring and is accompanied by
low birth weight [19–22]. Pregnancy complications, including pre-
eclampsia [23,24] and intrauterine growth restriction (IUGR) [25–
27] have been associated with reduced placental activity/
expression of HSD11B2.
Epigenetics is commonly studied in the context of developmen-
tal programming and DNA methylation is the most studied
epigenetic mark [28]. The placenta largely contributes to the fetal
environment through its endocrine and metabolic functions, in
addition to nutrient exchange. While this alone can influence
epigenetic susceptibility in the fetus, the placenta is also a target of
environmental effects (reviewed in [29]). Illustrative of potential
placental susceptibility to stress in utero, Wyrwoll et al. recently
reported altered methyl donor components, including folate,
methionine and choline in the placenta of rats exposed to
glucocorticoids [30].
DNA methylation of the NR3C1 exon 1F promoter is widely
studied, where altered methylation is observed in response to stress
stimuli in rat [31] and human [32–37] studies across multiple
tissues. DNA methylation is also proposed to regulate tissue-
specific HSD11B2 expression [38,39]; and has been associated
with placental HSD11B2 gene regulation in prenatally stress-
exposed rats [40]. In addition, CRH mRNA expression in the
human placenta is susceptible to increased maternal intake of the
methyl donor choline, which is associated with increased DNA
methylation of the CRH promoter [41].
The aim of this study was to assess the impact of placental
pathology, including pre-eclampsia and normotensive (n)IUGR
cases, on the DNA methylation status of several genes that are
linked to stress-induced pathways. For this purpose, pre-eclampsia
was further subdivided into two categories: those patients with
early onset symptoms arising ,34+0 weeks gestation (early onset
pre-eclampsia [EOPET]), or arising $34+0 weeks gestation (late
onset pre-eclampsia [LOPET]), the former of which carries a
considerably worse maternal and fetal prognosis [5]. A candidate
gene approach was undertaken through analysis of Illumina
Infinium HumanMethylation450 BeadChip array data targeting
.450,000 CpG sites across the human genome in a control and
EOPET subset, followed by confirmation and extension to
additional cohorts using bisulfite pyrosequencing.
Genes selected for analysis included those involved in 1) cortisol
signalling: NR3C1, CRH, and CRH receptor (CRHR1) and pro-
opiomelanocortin (POMC [ACTH precursor]), 2) cortisol bioavail-
ability: CRHBP and HSD11B2, and 3) placental hormonal
signalling: StAR-related lipid transfer domain protein 3 (STARD3),
CYP11A1, 3b-hydroxy-delta-5-steroid dehydrogenase type 1
(HSD3B1), TEA domain family member 3 (TEAD3) and CYP19.
Herein, we show the remarkable DNA methylation plasticity of
many genes involved in stress and hormone pathways associated
with the severe placental dysfunction present in EOPET.
Materials and Methods
Ethics Statement
This study was approved by the University of British Columbia
and the Children’s & Women’s Health Centre of British
Columbia. Women between the ages of 18 and 42 years were
recruited from the BC Women & Children’s Hospital, Vancouver,
during the second trimester of pregnancy following informed
written consent.
Subjects
Cases included in this study partially overlap other studies
published by our group [42–45]. Control cases consisted of
normotensive women with no known placental pathology. In order
to collect control samples at gestational ages matching that of case
cohorts, premature deliveries involving a range of causes such as
premature rupture of membranes, chorioamnionitis and cervical
incompetence were included. Pre-eclampsia was defined using the
Society of Obstetricians and Gynaecologists of Canada guidelines
[46] which include the following criteria: 1) hypertension (systolic
blood pressure $140 mmHg and/or diastolic blood pressure
$90 mmHg measured twice, at least 4 hours apart) after 20 weeks
gestation in combination with proteinuria ($0.3 g/d or $2+
dipstick proteinuria) or another adverse condition (non-hyperten-
sive and non-proteinuric haemolysis, elevated liver enzymes, low
platelet count (HELLP) syndrome, fetal IUGR; or absent or
reversed end-diastolic flow in the umbilical artery by Doppler
velocimetry). EOPET was defined as symptoms arising ,34+0
weeks and LOPET as symptoms arising $34+0 weeks gestation
[5]. nIUGR was defined as either: birth weight below the 3rd
percentile for gender and gestational age using Canadian
population parameters [47], or birth weight below the 10th
percentile in combination with a) persistent uterine artery notching
at 22+0 to 24+6 weeks, b) absent or reversed end diastolic velocity
on umbilical artery Doppler, and/or c) oligohydramnios (amniotic
fluid index ,50 mm) and absent maternal hypertension. Gesta-
tional diabetes, isolated maternal hypertension, non-singleton
pregnancies, still birth or fetal genetic anomaly cases were
excluded from the study.
Patient characteristics for the full cohort are outlined in Table 1.
As expected, birth weight was significantly lower in all case groups
compared to controls. Furthermore, IUGR co-existed with pre-
eclampsia in 14/19 EOPET and 5/18 LOPET cases. Gestational
age was not matched in pre-eclampsia and control cases and was
assessed as a confounder in DNA methylation studies. Where
possible, births were defined by the presence (spontaneous or
induced vaginal delivery) or absence (elective caesarean section) of
labour (Table 1). Emergency caesareans, or cases in which no data
were available, were undefined. Labour was therefore defined in
54/111 controls, 10/19 EOPET, 12/18 LOPET and 9/13
nIUGR patients. Of these cases there was unequal distribution
of labour/no labour births in EOPET and nIUGR patients
compared with controls (x2; P,0.001, P,0.05, respectively). Self-
reported ethnicity was available in only a minority of cases,
precluding evaluation of this as a separate variable. Of these, the
majority reported Caucasian (,60%) or Asian (,30%), with the
remainder of other or mixed ancestry.
Selection of Candidate Genes
A candidate gene approach was used to select a set of genes
known to be directly involved in stress hormone signalling,
availability and downstream actions, such as hormone production.
Data were collected from an Infinium HumanMethylation450
BeadChip array (Illumina Inc., San Diego, CA); genome-wide
results are being published separately by our group (Blair et al., in
preparation; GEO: GSE44667). Briefly, tissue (1 cm3) was sampled
from three chorionic villus sites and DNA extracted using standard
salting out methods. Equal amounts of placental DNA were
pooled from all three sites per placenta and bisulfite converted
using the EZ DNA methylation kit (Zymo Research Corp., Irvine,
CA) following the manufacturer’s instructions. A subset of
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gestational age and gender matched control (n = 19) and EOPET
(n= 19) placental DNA samples were run on the Infinium
HumanMethylation450 BeadChip array according to the manu-
facturer’s protocol. Raw data were read using GenomeStudio
(Illumina Inc.), colour-corrected [48], and batch-normalised.
Correction for probe type using SWAN [49] and removal of
probes targeting known SNPs was also performed [50]. Output
data were reported as b values, representing DNA methylation at
each locus within a range of 0–1. Each candidate gene was
associated with a range of 3 to 22 CpG probes, except NR3C1 for
which 37 associated CpG probes were located on the array. These
represented both upstream (enhancers and promoters) and gene
body regions. Significant differences in candidate gene DNA
methylation between groups were identified by any associated
CpG exhibiting a P-value of ,0.05, using a Mann-Whitney test.
Since the methylation detection limit for a single CpG by bisulfite
pyrosequencing is estimated to be ,5% [51], candidate CpG sites
for further assessment using this method were selected only when
the difference in b values (Db) were $7% between controls and
cases. Additionally, in situations where .1 CpG site per gene fit
this criteria, the site with the largest Db was selected; however, the
genomic location with respect to promoter or CpG island
proximity was also considered. In the case of NR3C1 two Illumina
CpG sites were selected for further analysis, to allow for a more
comprehensive assessment of the gene region proximal to
promoter 1D. In the case of HSD11B2, 11 CpG sites were
interrogated within the promoter region and included sites that
were shown to be differentially methylated in IUGR in the
literature [52].
Bisulfite Pyrosequencing
To assess CpG methylation in our extended cohort of controls
and cases, placental DNA samples were analysed using bisulfite
pyrosequencing. Forward, reverse and sequencing primers for
bisulfite converted DNA were designed with the aid of Pyro Q-
CpG software (Qiagen Ltd., GmbH, Hilden, Germany; Table S1).
PCR reactions consisted of ,20 ng bisulfite-converted DNA, 16
PCR buffer (Qiagen Ltd.), 0.2 mM dNTPs (Invitrogen, Carlsbad,
CA), 0.4 mM forward and reverse primers (Integrated DNA
Technologies Inc., Coralville, IA) and 0.18 U DNA polymerase
(HotStarTaq, Qiagen Ltd.). Optimised PCR conditions consisted
of 95uC for 15 min, 40 cycles of 95uC for 30 sec, variable
annealing temperature (Ta) for 30 sec, 72uC for 30 sec, and finally
72uC for 10 min. The optimal Ta was 51uC for CYP19, 55uC for
NR3C1 assay 1 and 2, CRHBP, CYP11A1, HSD3B1, HSD11B2 and
TEAD3, and 57uC for CRH PCR reactions. PCR products were
sequenced and DNA methylation analysed at each CpG site using
the Pyromark Q96 MD Pyrosequencer (Qiagen Ltd.). Samples
from each patient group were equally allocated to multiple
pyrosequencing plates to cancel out biases due to inter-plate
variability (,5% for each assay). Where possible, more than one
CpG site was included in the pyrosequencing assay, in addition to
the site identified using the DNA methylation array.
Gene Expression Array
Gene expression data were obtained using a subset of
gestational age and gender matched control (n = 8) and EOPET
(n= 8) cases that were run on the Illumina DNA methylation
array. RNA was extracted from one chorionic villus site stored at
280uC in RNAlater (Invitrogen), using the RNeasy kit (Qiagen
Ltd.) following the manufacturer’s protocol. RNA was assessed for
quality using the Bioanalyzer 2100 (Agilent, Santa Clara, CA),
reverse transcribed to cDNA (TotalPrep RNA Amplification kit,
Illumina, Inc.) and hybridised to a HT-12v4 Expression BeadChip
(Illumina, Inc.) according to the manufacturer’s protocol. This
chip interrogates .47,000 transcripts genome-wide. Raw data
were quantile normalised using GenomeStudio 2011 (Illumina,
Inc.) and probes with bad detection P-values were removed and
replaced with a value of zero. The full data set is being published
separately (Blair et al., in preparation; GEO: GSE44711). Expres-
sion data were available for all genes followed up in this study.
NR3C1 Isoform-specific Polymerase Chain Reaction (PCR)
NR3C1 exon 1C and exon 1D isoform-specific PCR was
performed across five chorionic villus samples obtained over
different gestational time points, including 7, 19, 24, 32 and 40
weeks of gestation. RNA was extracted from tissue samples stored
at 280uC in RNAlater using the phenol-chloroform method
Table 1. Patient characteristics for cases assessed by bisulfite pyrosequencing.
Parameter Controls n=111 EOPET n=19 LOPET n=18 nIUGR n=13
Birth weight (g) 25906989 13996621 27426798 21326513
Birth weight (SD) 0.0660.07 21.5160.22*** 20.7360.29** 21.6760.20***
Co-existing IUGR – 14/19 5/18 –
Gestational age (weeks) 35.0964.21 31.9363.27* 37.4762.29* 36.4362.31
Maternal age (years) 33.1064.74 34.1666.01 33.4965.47 34.6465.26
Female: Male ratio 55:56 7:12 10:8 9:4
Mode of delivery
Labour 46 4 9 5
No Labour 8 6 3 4
Undefined 57 9 6 4
Birth weight statistics are based on standard deviation (SD) points relative to gestational age and gender matched normal birth weight ranges. Gestational age values
are given at birth. Data are mean 6 SD. The mode of delivery is characterised as ‘Labour’ (spontaneous or induced vaginal delivery), ‘No Labour’ (elective caesarean
section) or, ‘Undefined’: emergency caesarean section or unknown. EOPET: early onset pre-eclampsia, LOPET: late onset pre-eclampsia, nIUGR: normotensive
intrauterine growth restriction,
*P,0.05,
**P,0.01,
***P,0.001, compared to controls.
doi:10.1371/journal.pone.0062969.t001
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(TRIzol, Invitrogen) according to the manufacturer’s protocol.
Commercially available adult male hippocampus RNA was used
as a positive control for NR3C1 exon 1D expression (BioChain
Institute, Inc., Newark, CA). RNA concentrations and purities
were measured using the Nanodrop 1000 spectrophotometer
(ThermoScientific, Wilmington, DE). cDNA was prepared from
200 ng RNA using the High Capacity RT kit (Applied Biosystems
Inc., Foster City, CA). A negative control reaction was prepared
through the omission of reverse transcriptase. PCR primer
sequences were exon-exon spanning: NR3C1 exon 1D forward
primer 59-ACCCTAAACCCACACAGCAC-39, NR3C1 exon 1C
forward primer 59-GGGCAATGGGAGACTTTCTT-39, and a
shared NR3C1 exon 1C/D reverse primer 59-TCCATCA-
CATCTCCCCTCTC-39. Amplicon length for NR3C1 exon 1C
and 1D transcripts were 288 and 159 base pairs, respectively. PCR
reactions were prepared as described in section 2.4, using 1 uL
cDNA and a Ta of 60uC for both assays. PCR products were run
on a 1% standard agarose gel at 120 V for 45 min, alongside a 100
base pair DNA ladder (Invitrogen) and visualised using a Universal
Hood II gel imager and Quantity One v4.6.9 software (Bio-Rad,
Hercules, CA).
Statistics
Patient clinical data were compared using a Student’s t-test,
non-parametric Mann-Whitney test or a chi-squared test where
appropriate. DNA methylation array data for control and EOPET
cases were compared using a Mann-Whitney test. For bisulfite
pyrosequencing analyses, Spearman’s Rho correlation coefficients
were calculated to determine CpG correlation within an assay.
Univariate linear regression analyses were performed in control
and case cohorts to identify potential confounding factors that
influence mean DNA methylation at a selected gene. Variables
assessed included birth weight, gestational age at birth, maternal
age, gender of infant and the presence/absence of labour. If
confounding factors were absent, an analysis of variance was used
to compare control, EOPET, LOPET and nIUGR groups. If
confounding factors were present, an analysis of covariance
correcting for that variable was applied. All analyses included a
Levene’s test for equality of error variances and were followed by
Bonferroni post-hoc tests for multiple comparisons. RNA expres-
sion array data for control and EOPET cases were compared
using a Student’s t-test or Mann-Whitney test as appropriate. P-
values of ,0.05 were considered significant.
Results
Candidate Genes for Differential Placental DNA
Methylation in Pre-eclampsia
Multiple genes associated with stress pathways and steroid
production were associated with differentially methylated CpG
sites in EOPET cases compared with controls based on the
Illumina DNA methylation array (Table 2). In the region
containing alternative NR3C1 exon 1s and respective upstream
promoters, differential DNA methylation was observed at CpG
sites adjacent and upstream of exon 1D (Fig. 1). In EOPET
placentae there was significant hypermethylation of these sites
compared to controls (Fig. 1; Table 2). Interestingly, no other
NR3C1 promoter regions, including the widely studied exon 1F
region, were altered in EOPET placentae. In fact, in normal
placentae CpG sites across the NR3C1 promoter region were
largely unmethylated (b value 0–0.1), with the exception of exon
1D in which DNA methylation values were greater (b value 0.1–
0.3; Fig. 1).
Regions associated with other candidate genes also exhibited
altered placental DNA methylation patterns in control versus
EOPET cases (Table 2). A CpG island associated with CRHBP
(Fig. S1) was significantly hypermethylated in EOPET, whereas
non-CpG island regions associated with CRH, CYP11A1, HSD3B1,
TEAD3 and CYP19 were hypomethylated in EOPET versus
control placentae (Fig. S2-6, respectively). A CpG associated with
the transcription factor TEAD3 was particularly altered, with an
average b value decrease of 0.21 in EOPET (P,0.0001). DNA
methylation values between control and EOPET groups were
altered by $0.1, or 10% points, at CpG sites within steroidogenic
pathway genes including CYP11A1, HSD3B1 and CYP19 (all
P,0.0001). Candidate genes that were assessed but revealed no
alteration in placental DNA methylation patterns at individual
CpG sites in control and EOPET cases included CRHR1,
HSD11B2, POMC, STARD3 and CYP17 (data not shown).
Bisulfite pyrosequencing was performed to confirm DNA
methylation differences at significant CpG sites in a larger cohort
of controls as well as cases of LOPET and nIUGR. For control
and EOPET samples that were assessed by both array and
pyrosequencing techniques, DNA methylation values at investi-
gated CpG sites for the two methods were highly correlated (all
loci Spearman’s Rho.0.8; P,0.001). Within pyrosequencing
assays, DNA methylation values at individual CpG sites were also
correlated (Fig. S7), and therefore mean methylation values for
each region were compared.
Gestational Age, but not Presence/absence of Labour, is
a Confounder of Placental DNA Methylation at Candidate
Genes
Using the bisulfite pyrosequencing data, univariate linear
regression analyses for each studied region were performed on
control and case cohorts to determine whether specific known
patient variables might influence DNA methylation in that cohort.
Birth weight, maternal age and infant gender were not significant
confounders in any group assessed (data not shown). Gestational
age significantly influenced DNA methylation in third trimester
control placentae (n = 111; range 28–40 weeks) in a gene
dependent manner. Increasing gestational age was negatively
associated with CpG methylation within targeted regions of CRH
(R=20.19; P,0.05), CYP19 (R=20.27; P,0.01), TEAD3
(R=20.51; P,0.0001) and HSD3B1 (R=20.36; P,0.001)
genes, and positively associated with CpG methylation of CRHBP
(R= 0.26; P,0.01). However, there was no significant effect of
gestational age on CpG methylation of the NR3C1 exon 1D
promoter region (R=20.03) nor CYP11A1 (R=20.13). Conse-
quently, gestational age was corrected for in those genes in which
it was found to be a confounder. It should be noted that even
though the EOPET cases were on average of an earlier gestational
age than controls, the methylation trends in EOPET were
generally in the opposite direction than expected based on these
gestational age associations.
Since the process of labour can induce gene expression changes
in the placenta [53,54], we assessed whether or not labour affected
DNA methylation at the genes included in this study. In a clearly
defined subset of control patients, those that experienced labour
(n = 46) and those that did not (n = 8), were compared. Although
sample size in the non-labour group was small and mode of
delivery data were not available for the full cohort, preliminary
data suggested no significant DNA methylation changes at any of
the genes/CpG sites studied as a result of labour (data not shown).
As changes in DNA methylation may be dependent on cell
replication, labour would not be expected to be associated with
large changes in DNA methylation, and this confirms that the
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Figure 1. CpG sites on the Illumina Infinium HumanMethylation450 BeadChip array across the NR3C1 gene region. Upper graph: DNA
methylation at each CpG site in control (n = 19) and early onset pre-eclampsia (EOPET; n = 19) placentae. Lower graph: enlargement of region
associated with CpG island containing multiple alternative first exons (black boxes). The Illumina CpG probe identifier is indicated by cg# and the
position of CpG sites on the graphs are not to scale. *P,0.05.
doi:10.1371/journal.pone.0062969.g001
Table 2. Illumina Infinium HumanMethylation450 BeadChip array data.
Gene
Chromosome
location CpG of interest Gene region CpG island? DNA methylation (b value) D b P-value
Control EOPET
NR3C1 ch5 (q31.3) cg14558428 exon 1D promoter Y 0.1460.08 0.2360.12 0.09 0.01
NR3C1 ch5 (q31.3) cg24026230 exon 1D promoter Y 0.1160.06 0.1960.13 0.08 0.02
CRH ch8 (q13.1) cg23409074 exon 1 (59 UTR) N 0.3760.12 0.2960.06 20.08 0.03
CRHBP ch5 (q13.3) cg13777717 intron 3 Y 0.4060.08 0.4860.07 0.08 0.001
CYP11A1 ch15 (q24.1) cg06285340 exon 1 N 0.5460.03 0.4260.04 20.12 ,0.0001
HSD3B1 ch1 (p12) cg16175792 exon 2 N 0.8260.02 0.6960.05 20.13 ,0.0001
TEAD3 ch6 (p21.31) cg10893014 intron 1 N 0.6060.06 0.3960.10 20.21 ,0.0001
CYP19 ch15 (p21.2) cg15329467 placental-specific exon 1.1
promoter
N 0.5660.05 0.4660.05 20.10 ,0.0001
The Illumina CpG of interest, gene location and CpG island (defined as length .200 base pairs, 50% GC content and .0.6 CG ratio) association is provided. Mean 6 SD
methylation b values and P-values are given for each gene for control (n = 19) and early onset pre-eclampsia (EOPET; n = 19) placental samples. NR3C1: nuclear receptor
subfamily 3, group C, member 1, CRHBP: corticotropin releasing hormone (CRH) binding protein: HSD3B1:3b-hydroxy-delta-5-steroid dehydrogenase type 1, TEAD3: TEA
domain family member 3.
doi:10.1371/journal.pone.0062969.t002
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methylation changes we observed are unlikely to be altered by
short term exposures at the end of pregnancy.
Glucocorticoid Signalling Pathway Genes are
Differentially Methylated in Pre-eclampsia
Differential placental DNA methylation of NR3C1, proximal to
the exon 1D promoter, was verified in EOPET cases at multiple
CpG sites by bisulfite pyrosequencing. Average DNA methylation
values were significantly increased across the NR3C1 exon 1D
region compared with controls (+8.46%; P,0.01; Fig. 2A). In
addition, there were trends indicative of increased DNA methyl-
ation at this locus in LOPET placentae relative to controls (+6.4%;
P=0.09; Fig. 2A). Increased promoter methylation of NR3C1
could be a feature of both early and late pre-eclampsia, but
perturbations are more pronounced in the earlier onset cases.
Alternatively, a subset of cases classified as LOPET may have a
placental aetiology more similar to EOPET, causing a trend
towards similar changes. While NR3C1 DNA methylation trends
for nIUGR cases appeared similar to that of LOPET placentae,
mean methylation differed from controls by ,5% and was not
significantly altered (Fig. 2A).
Genes involved in the hormonal regulation of glucocorticoid
levels were also followed up with bisulfite pyrosequencing. In line
with DNA methylation array findings, there was a non-significant
trend for decreased CpG methylation at the CRH gene in EOPET
placentae (59 UTR; 24.30%; P=0.11; Fig. 2B) and an opposing
significant increase in DNA methylation associated with CRHBP
(intron 3; +9.14%; P,0.05; Fig. 2C), compared with controls.
However, DNA methylation at these CpG sites was not
significantly altered in LOPET or nIUGR placentae relative to
controls.
Steroidogenic Pathway Genes are Differentially
Methylated in Pre-eclampsia
The shift in DNA methylation at Illumina CpG sites associated
with steroidogenic genes was confirmed in pre-eclampsia-associ-
ated placentae by bisulfite pyrosequencing. In EOPET there were
significant losses of DNA methylation at regions associated with
CYP11A1 (exon 1; 29.66%; P,0.00001; Fig. 3A) and HSD3B1
(exon 2; 212.49%; P,0.00001; Fig. 3B) compared with controls.
In addition, the same loci were perturbed in LOPET cases
(CYP11A1: –.5.77%; P,0.001 and HSD3B1: 26.88%; P,0.001).
TEAD3 was significantly hypomethylated in EOPET compared
with controls (intron 1;212.56%; P,0.00001), but not in LOPET
placentae (Fig. 3C). Similarly, hypomethylation of CpG sites
associated with CYP19 in EOPET cases (exon 1.1; 210.6%;
P,0.0001; Fig. 3D), was not present in LOPET cases compared
with control placentae. In addition, there was no significant
association of isolated nIUGR with placental DNA methylation
found for any of the steroidogenic genes studied (Fig. 3).
DNA Methylation of the HSD11B2 Promoter is not
Altered in nIUGR
We elected to assess HSD11B2 promoter DNA methylation by
bisulfite pyrosequencing in our nIUGR cohort, targeting 11
consecutive CpG sites including four CpG sites previously
Figure 2. Placental DNA methylation of genes involved in cortisol signalling and bioavailability. DNA methylation at CpG sites within A)
exon 1D promoter of the nuclear receptor subfamily 3, group C, member 1 (NR3C1), B) corticotropin releasing hormone (CRH) and C) CRH binding
protein (CRHBP) genes. Control, early onset pre-eclampsia (EOPET), late onset pre-eclampsia (LOPET) and normotensive intrauterine growth restriction
(nIUGR) placentae are compared. Median and interquartile ranges are given based on average assay CpG methylation measured by bisulfite
pyrosequencing. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0062969.g002
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associated with birth weight across normal ranges and increased
DNA methylation in IUGR cases [52]. Methylation values at
different CpG sites across this region were variable and were not
correlated (Fig. S7); therefore DNA methylation was assessed at
individual CpG sites. Univariate linear regression analyses
revealed no confounding effect of gestational age, maternal age,
infant gender or mode of delivery (data not shown). Also, there was
no significant relationship between birth weight and HSD11B2
promoter DNA methylation across normal birth weight ranges in
our cohort of 111 controls (Table S2). Furthermore, we did not
observe altered HSD11B2 promoter methylation between control
and nIUGR cases (Fig. 4A and B). Pyrosequencing for EOPET
and LOPET cohorts also confirmed no change in DNA
methylation values at this locus in pre-eclampsia (Fig. 4A and
B), as previously indicated by DNA methylation array data.
DNA Methylation is Inversely Associated with mRNA
Expression for Selected Genes
Gene expression array data were available for a small subset of
matched control and EOPET cases overlapping the larger cohort.
Significant upregulation of CRH (.20 fold), CYP11A1 (4 fold),
HSD3B1 (5 fold) and CYP19 (5 fold) transcripts was observed in
EOPET cases compared to controls (Table 3; all P,0.01) but not
TEAD3. Also, there were trends for the downregulation of CRHBP
and upregulation of HSD11B2 expression in EOPET-associated
placentae (Table 3). The expression of NR3C1 mRNA was not
altered; however, as the probe to detect NR3C1 mRNA was not
transcript-specific, it is possible that subtle changes in isolated
transcript expression would not be detected.
In addition, gene expression across both control and EOPET
groups was inversely correlated with DNA methylation in
promoter regions of CRHBP (R=20.70, P,0.01), CYP11A1
(R=20.76; P,0.01), HSD3B1 (R=20.55; P=0.05) and CYP19
(R=20.36) genes, although not CRH (R=20.05).
The NR3C1 Exon 1D Transcript is Expressed in Placenta
Across Gestation
Isoform-specific PCR was performed for NR3C1 exon 1C and
exon 1D to determine their expression in the placenta over
gestation (Fig. 5). The ubiquitously expressed exon 1C was
observed across all gestational ages assessed including 7, 19, 24, 32
and 40 week gestationally aged placental samples. The exon 1D
transcript was also expressed in the placenta across these
developmental stages. Since this transcript has been previously
reported only in the adult hippocampus, and absent from a range
of other tissues [55], expression of NR3C1 exon 1D may be of
particular importance in the placenta.
Discussion
The majority of normotensive pregnancies are characterised by
the absence of placental cortisol; however, cortisol is detectable in
the placenta of up to 80% of pre-eclampsia-associated pregnancies
[24]. This is of concern given the overwhelming evidence for the
role of glucocorticoids in the developmental programming of
disease. This is documented in both animal and human studies,
Figure 3. Placental DNAmethylation of genes involved in steroidogenesis. DNA methylation at CpG sites within A) CYP11A1, B) 3b-hydroxl-
delta-5-steroid dehydrogenase type I (HSD3B1), C) TEA domain family member 3 (TEAD3) and D) CYP19 genes. Control, early onset pre-eclampsia
(EOPET), late onset pre-eclampsia (LOPET) and normotensive intrauterine growth restriction (nIUGR) placentae are compared. Median and
interquartile ranges are given based on average assay CpG methylation measured by bisulfite pyrosequencing. ***P,0.001.
doi:10.1371/journal.pone.0062969.g003
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and is associated with low birth weight, hypersensitive stress
response and neurobehavioural anomalies in infants, and
increased risk of metabolic, cardiovascular and reproductive
syndromes in adults (reviewed in [1,56,57]). Determining the
types of pregnancies that are at elevated risk for such program-
ming events and understanding the mechanisms that lead to these
changes may permit future advancements in obstetrical and
neonatal care and improved long-term health outcomes.
The human NR3C1 gene contains multiple tissue-specific
alternative first exons, each containing upstream promoters that
can be silenced by DNA methylation [55,58]. Previously, altered
DNA methylation at specific CpG sites within the exon 17
promoter in rat hippocampi [31,59], and in the human orthologue
exon 1F in brain, peripheral and cord blood, and placenta
[32,34,35,37], has been associated with perinatal or prenatal
stress. In the placenta, DNA methylation at NR3C1 exon 1F
promoter is associated with neurological and mental health
outcomes in infants in normal pregnancy [36] and in babies large
for gestational age [60]. The biological impact of the small DNA
methylation changes (1–5% points) reported at the exon 1F
promoter, a region exhibiting very low levels of methylation
(,10%), is not clear.
In this study, promoter-wide DNA methylation profiling
revealed differential patterns at the exon 1D promoter, but not
at exon 1F. Levels of DNA methylation in the exon 1D region
ranged from 5–40% in normal placenta, agreeing with previous
Figure 4. Placental DNA methylation of the 11b-hydroxysteroid dehydrogenase type 2 (HSD11B2) promoter. Control, early onset pre-
eclampsia (EOPET), late onset pre-eclampsia (LOPET) and normotensive intrauterine growth restriction (nIUGR) placentae are compared. Mean 6 SD
DNA methylation values are given for consecutive CpG sites in HSD11B2 assay 1 (A) and assay 2 (B) measured by bisulfite pyrosequencing.
doi:10.1371/journal.pone.0062969.g004
Table 3. Illumina HT-12v4 Expression BeadChip gene
expression array data for genes followed up by bisulfite
pyrosequencing.
Gene Array probe
RNA expression
(Fluorescent Units) P-value
Control EOPET
NR3C1 ILMN_2389347 59.4616.3 57.8612.2 NS
CRH ILMN_1668035 64.22620.6 143161124 ,0.01
CRHBP ILMN_1761312 153.96137.6 90.7690.5 NS
CYP11A1 ILMN_1768820 442.86277.2 175061377 ,0.01
HSD3B1 ILMN_1780693 238.46120.2 11936857 ,0.01
TEAD3 ILMN_1814002 118.9644.9 119.9638.8 NS
CYP19 ILMN_2387860 112.0654.6 671.46579.8 ,0.01
HSD11B2 ILMN_1813350 37.4621.5 148.66294.2 NS
The Illumina probe identifier, mean 6 SD expression values and the associated
P-value is given for each gene for a subset of control (n = 8) and early onset pre-
eclampsia (EOPET; n = 8) placental samples. NR3C1: nuclear receptor subfamily
3, group C, member 1, CRHBP: corticotropin releasing hormone (CRH) binding
protein: HSD3B1:3b-hydroxy-delta-5-steroid dehydrogenase type 1, TEAD3: TEA
domain family member 3, HSD11B2:11b-hydroxysteroid dehydrogenase type 2.
doi:10.1371/journal.pone.0062969.t003
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reports of large interindividual variation within the NR3C1
promoter [61]. While this interindividual variation was also
present in pathological placentae, DNA methylation values were
on average significantly higher than normal placentae, providing
evidence that at least in the human placenta, exon 1D may be
more susceptible to environmental insults than alternative
promoter regions. The interrogated CpG sites were proximal to
the putative consensus sequence (CGCCATnTT) for the ubiqui-
tously expressed zinc finger transcription factor Yin Yang 1 (YY1),
in addition to various other transcription factor motifs located in
the exon 1D promoter [61]. Given the proximity of these
consensus sequences to regions of differential DNA methylation
in our study, we speculate that altered DNA methylation may be
representative of an altered transcriptional landscape in these
cases. In addition to gene expression being transiently influenced
by events in the perinatal period, such as mode of delivery, it can
also be affected by placental processing time; while such factors
have not been shown to have major effects on DNA methylation
[62].
Given the complexity of NR3C1 gene regulation and the fact
that alternative splice variants are expressed in the placenta before
and after labour [54], we wished to determine if the differentially
methylated promoter, exon 1D, was expressed in the placenta.
Previous reports indicated that exon 1D was exclusively expressed
in adult hippocampal tissue and was absent from a panel of adult
peripheral tissues and cells [55]. We found that NR3C1 exon 1D is
expressed in the human placenta over gestational ages ranging
from the first to the third trimester. Of interest, this promoter
region exclusively maps to histone-3 lysine-4 mono-methylation
‘active’ marks across numerous cell lines, is predicted to be within
a strong enhancer region according to ENCODE and is contained
within a DNase I hypersensitivity cluster. These observations
suggest a regulatory role for the promoter region upstream of exon
1D that could be involved in overall NR3C1 expression.
During development the HPA axis is susceptible to altered
programming, of which the CRH signalling system is a target [21].
In rats, in utero exposure to stress elevates cortisol in offspring,
which is associated with increased hypothalamic CRH expression
[63], and decreased CRHBP and increased ACTH plasma
concentrations [64,65], indicating increased adrenal cortisol
production and bioavailability. Like the hypothalamic isoform,
placental CRH can stimulate maternal and fetal adrenal
steroidogenesis, as well as placental hormone production, specif-
ically repressing progesterone [66] and augmenting estrogen [14]
synthesis in trophoblasts.
In women with high third trimester choline supplementation, a
4–5% increase in DNA methylation at CpG sites within the CRH
promoter in placenta was associated with a ,33% fall in placental
CRH transcript levels and cord blood cortisol concentration,
suggesting a direct effect on the fetal HPA axis [41]. As these DNA
methylation changes were observed at CpG sites adjacent to the
sites included in our study, an equivalent decrease in DNA
methylation levels in EOPET compared to controls may reflect
increased transcript levels. Indeed, placental CRH content and
umbilical cord and maternal plasma CRH are significantly
elevated in pre-eclampsia-associated pregnancies compared to
normal pregnancies [67–71]. In this study, we further confirmed
an increase in placental CRH mRNA in a subset of pre-eclampsia
cases, although we did not observe a relationship between DNA
methylation at these particular CpG sites and transcript expression
in this small number of cases.
Elevated CRH has been reported in umbilical cord plasma of
IUGR infants [72]. However, we found no change in CRH DNA
methylation levels in placentae of nIUGR pregnancies in our
study. While multiple regulatory processes in addition to DNA
methylation can influence CRH gene expression, it is also possible
that IUGR cases utilised in other studies included cases with co-
existing hypertension/pre-eclampsia that might have contributed
to altered CRH levels. Increased CRHR1 gene expression was also
reported in placentae of complicated pregnancies including pre-
eclampsia and IUGR [73]; however, we did not detect altered
DNA methylation of the CRHR1 gene in this study.
Intragenic DNA methylation can be associated with altered
gene expression, and may regulate alternative promoters [74]. In
EOPET-associated placentae, we observed hypermethylation of
CRHBP at CpG sites contained within a CpG island overlapping
the third intron. There was an inverse relationship between DNA
methylation at this region and RNA expression across a subset of
control and EOPET cases and a trend for downregulation of
CRHBP mRNA in pre-eclampsia-associated placentae. Other
studies have found reciprocal decreases in CRHBP and increases
in CRH transcripts in the placenta [75] or protein levels in the
plasma [70] of women who developed pre-eclampsia. Thus,
elevated levels of circulating CRH, through increased placental
CRH and/or decreased CRHBP production may be a mechanism
to stimulate increased downstream glucocorticoid synthesis.
The physiological elevation of maternal glucocorticoids during
the third trimester is normally counteracted by the concurrent
upregulation of placental HSD11B2 [25]. Adverse effects of
glucocorticoid exposure through the inhibition of placental
HSD11B2 expression/11bHSD type 2 activity in offspring are
well documented [19,20,22,76], and have been associated with
hypermethylation of CpG sites within the Hsd11b2 promoter in
rats [40]. Despite lowered placental HSD11B2 expression being
reported in pre-eclampsia [23,24], DNA methylation patterns
across the HSD11B2 promoter and gene regions were not altered
in our cohort. Additionally, we found only a moderate trend for
HSD11B2 mRNA downregulation in our sample subset. Further-
Figure 5. NR3C1 isoform expression in the human placenta.
Expression of NR3C1 exon 1C and 1D alternative transcripts in the
placenta across gestation. A cDNA reaction prepared from adult male
hippocampus RNA was used as a positive control. The negative control
consisted of a cDNA reaction omitting reverse transcriptase. NR3C1
exon 1C and 1D PCR amplicons were 288 base pairs (bp) and 159 bp in
length, respectively.
doi:10.1371/journal.pone.0062969.g005
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more, there was no relationship between HSD11B2 promoter
DNA methylation and birth weight, as indicated in a previous
study [52].
To sustain considerable estrogen and progesterone synthesis
required for placental function and pregnancy maintenance, the
placental syncytiotrophoblast abundantly express steroidogenic
pathway genes [77]. In the placenta, a structural homologue to
steroidal acute regulatory protein, STARD3, transports cholesterol
for conversion to pregnenolone by cytochrome P450 side chain
cleavage (encoded by CYP11A1) [78,79]. DNA methylation of
CpG sites at the promoters of STARD3 and CYP11A1 genes was
assessed given their rate limiting involvement in placental
steroidogenesis. Placental DNA methylation patterns associated
with STARD3 were unaltered among cases; however, there was
significant hypomethylation of CYP11A1 in pre-eclampsia cases
compared with controls. Furthermore, our findings of upregula-
tion of CYP11A1 in pre-eclampsia-associated placentae, and a
negative correlation between placental CYP11A1 DNA methyla-
tion and RNA expression support a role for DNA methylation in
regulating CYP11A1 expression. The transcription factor activating
protein 2 (AP2) is proposed to transactivate CYP11A1 in the
placenta [80] and the binding of this factor to gene promoters is
sensitive to DNA methylation in other tissues [81]. Based on the
DNA methylation array data, the differential DNA methylation
observed in pre-eclampsia-associated placentae is likely to extend
into this consensus sequence located ,100 base pairs upstream of
interrogated CpG sites.
The placental production of up to 250–300 mg progesterone
per day is maintained by the conversion of pregnenolone into
progesterone by 3b-hydroxysteroid dehydrogenase type 1
(3bHSD1 encoded by HSD3B1) [77]. Placental-specific enhancers
are located 2500–3000 base pairs upstream of the HSD3B1
promoter, and contain a binding site for transcription enhancer
factor 5 (TEF-5; encoded by TEAD3), which is predominantly
expressed by the placenta [82] and necessary to confer placental-
specific HSD3B1 expression [83]. Regions associated with both
Figure 6. Model of altered stress and hormonal signalling gene-pathways in pre-eclampsia. Left hand side: summary of altered DNA
methylation at specific CpG sites across candidate genes, where black and white circles indicate gain or loss of methylation, respectively. Coding
regions are indicated by black rectangles and transcription factor (TF) binding motifs are represented by grey circles and include yin yang 1 (YY1;
putative), activated protein 2 (AP2; known) and transcription enhancer factor 5 (TEF5; known). Bent lines represent transcription start sites: arrow or
blunt heads hypothesise increased or decreased expression, respectively. Green bars represent CpG islands. Annotations are of approximate location
and distance. Right hand side: hypothesised model of the downstream effects of altered placental DNA methylation at candidate genes. NR3C1:
nuclear receptor subfamily 3, group C, member 1, CRH: corticotropin releasing hormone, CRHBP: CRH binding protein, HSD3B1:3b-hydroxy-delta-5-
steroid dehydrogenase type 1, TEAD3: TEA domain family member 3, GR: glucocorticoid receptor, HSD11B2:11b-hydroxysteroid dehydrogenase type
2, P450scc: P450 side chain cleavage, 3bHSD1:3b-hydroxysteroid dehydrogenase type 1.
doi:10.1371/journal.pone.0062969.g006
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HSD3B1 (exon 2) and TEAD3 (intron 1) were significantly
hypomethylated in EOPET placentae suggesting a propensity
for altered expression of steroidogenic genes. HSD3B1 mRNA was
significantly elevated in EOPET placentae. Therefore, loss of
DNA methylation at exon 2 may be associated with increased
3bHSD1 levels in the placenta and enhanced production of steroid
hormone precursors. We did not find altered expression of TEAD3
mRNA in EOPET cases; however, mRNA expression in the third
trimester may not represent transcript expression across gestation.
Since DNA methylation is relatively stable, it is possible that these
differences reflect expression earlier in gestation, and that the
differential methylation levels represent an altered chromatin
structure that permits interaction with transcription factors at
specific gestational time points.
Steroidogenic genes necessary for estrogen synthesis, including
CYP17 (17a-hydroxylase; synthesises androgenic precursors) and
CYP19 (aromatase) were also studied. While DNA methylation of
CYP17 was not altered, significant hypomethylation was observed
in the CYP19 promoter in EOPET placentae. Human CYP19
expression is controlled by tissue-specific promoters upstream of
alternative first exons [84]. In this study, the differentially
methylated CpG region in EOPET was contained within the
placental-specific CYP19 exon 1.1 promoter [85]. At other tissue-
specific human CYP19 promoters, DNA methylation has been
associated with CYP19 expression [86,87]. We found significant
up-regulation of CYP19 mRNA in EOPET placentae and a trend
for a negative association between CYP19 DNA methylation of the
exon 1.1 promoter and transcript expression. Therefore, DNA
methylation may also play a prominent role in tissue-specific
regulation of placental CYP19; however a larger sample size is
required to confirm this.
It was somewhat surprising that the altered DNA methylation
found in cortisol-signalling and hormone production genes was
limited to pre-eclampsia and not observed in nIUGR cases. Birth
weight was not a predictor of DNA methylation in any of the
genes/CpG sites included in this study. Pre-eclampsia was
accompanied by IUGR in 14/19 EOPET and 5/18 LOPET
cases; however, we did not find significant effects of IUGR within
pre-eclampsia groups. It is important to include isolated IUGR
cases as a control group to delineate the effects of fetal and
placental growth restriction with that of pre-eclampsia. Further-
more, the majority of DNA methylation changes were limited to
early onset rather than late onset disease, supporting the idea that
EOPET is aetiologically distinct to LOPET and that the cut-off of
34 weeks can distinguish cases with relatively greater placental
involvement, rather than manifestations of disease primarily in the
mother [88–92]. However, there was some overlap, in which
hypomethylation of CYP11A1 and HSD3B1 genes was present in
LOPET cases. Certain changes may occur in response to common
features such as exposure to anti-hypertensive medication, even if
the underlying pathology is different. Changes unique to EOPET
may reflect more fundamental aetiological differences.
We report altered DNA methylation proximal to genomic
regions previously characterised as important for gene regulation,
which is correlated with RNA expression in some cases. These
data may represent common dysregulation of stress and hormonal
pathways in pre-eclampsia. The biological consequences of altered
expression of cortisol signalling and endocrine genes in the
placenta in pre-eclampsia are likely to be complex and are
hypothetically modelled in Figure 6. Reduced placental GR
activation in combination with elevated CRH output may
stimulate both maternal and fetal adrenal cortisol synthesis
[10,12] thus aberrantly increasing fetal exposure to glucocorticoids
during development. Elevated CRH may also exert direct effects
on placental function, including effects on glucose uptake and
vascular tone and may contribute to the premature timing of
labour common to pre-eclampsia [15]. While CRH stimulates
placental estrogen synthesis (CYP19 expression) [14], its repressive
effect on progesterone synthesis (CYP11A1 and HSD3B1 expres-
sion) [66] may be dampened in the pre-eclampsia-associated
placenta. Maternal progesterone, but not estrogen, concentrations
are increased in women with preeclampsia [93,94] and both
steroid hormones positively stimulate CYP11A1 and HSD3B1
expression in trophoblast cells [95]. Therefore elevated progester-
one, despite elevated CRH, may act in a compensatory feed-
forward loop to promote placental steroidogenesis.
In summary, we suggest that changes in DNA methylation may
contribute to the altered expression of cortisol-signalling genes
previously linked to pre-eclampsia, and exclude this mechanism as
an important regulatory factor in other related pregnancy
complications. In addition, we highlight previously uncharac-
terised genes involved in placental steroidogenesis as differentially
methylated in pre-eclampsia. Additional functional characterisa-
tion of these genes is required to further assess the relationship
between DNA methylation and gene expression in the human
placenta and will form the basis of future experiments. Unravelling
which genetic pathways are susceptible to epigenetic modification
in the placenta may provide a clearer aetiological perspective in
disease cases and basis for targeted intervention.
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Methylation450 BeadChip array across the CRHBP gene
region. Upper panel: UCSC genome browser shot detailing
location of Illumina CpG probes, histone marks predictive of
enhancers, CpG island(s) and conserved transcription factor
binding sites (TFBS) associated with the gene body. Lower panel:
DNA methylation pattern at Illumina CpG sites across the
corticotropin releasing hormone binding protein (CRHBP) gene
region in control (n = 19) and early onset pre-eclampsia (EOPET;
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scale. Values are mean 6 SD, and *P,0.05 based on Mann-
Whitney tests.
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binding sites (TFBS) associated with the gene body. Lower panel:
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corticotropin releasing hormone (CRH) gene region in control
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Figure S3 CpG sites on the Illumina Infinium Human-
Methylation450 BeadChip array across the CYP11A1
gene region. Upper panel: UCSC genome browser shot
detailing location of Illumina CpG probes, histone marks
predictive of enhancers, CpG island(s) and conserved transcription
factor binding sites (TFBS) associated with the gene body. Lower
panel: DNA methylation pattern at Illumina CpG sites across the
CYP11A1 gene region in control (n = 19) and early onset pre-
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region in control (n = 19) and early onset pre-eclampsia (EOPET;
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Whitney tests.
(DOCX)
Figure S5 CpG sites on the Illumina Infinium Human-
Methylation450 BeadChip array across the TEAD3 gene
region. Upper panel: UCSC genome browser shot detailing
location of Illumina CpG probes, histone marks predictive of
enhancers, CpG island(s) and conserved transcription factor
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